A Phase 3 interventional study of Placebo and Ixekizumab 80 mg Q4W in Psoriatic Arthritis, sponsored by Eli Lilly and Company. Completed at 109 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-01.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 64th largest by enrollment of the 158 interventional ones that give a count, is one of 10 that started in 2014, is one of 71 in phase 3, and was the 59th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 10 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 363 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 158 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 193 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 8 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 16 to your calendar (.ics) → With an account.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
Drug: Placebo · Drug: Ixekizumab 80 mg Q2W
Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
Drug: Placebo · Drug: Ixekizumab 80 mg Q4W
Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).
Drug: Placebo
Administered SC
Administered SC
Also known as: LY2439821
Administered SC
Also known as: LY2439821
Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)
ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).
Time frame: Week 24
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
HAQ-DI is a participant reported questionnaire that measures disease-associated disability(physical function).It consists of 24 questions with 8 domains: dressing/grooming,arising,eating,walking,hygiene,reach,grip and other daily activities. The disability section scores the participant's self-perception on degree of difficulty (0=without any difficulty,1=with some difficulty,2=with much difficulty,3=unable to do)covering the 8 domains.The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.The reported use of special aids/devices and/or the need for assistance of another person to perform these activities is assessed.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment,baseline score,geographic region, TNFi experience,visit, treatment-by-visit interaction(itcn), geographic region-by-visit itcn,TNFi experience-by-visit itcn and baseline score-by-visit itcn.
Time frame: Baseline, Week 24
Percentage of Participants Achieving ACR20
ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 12
Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)
ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 24
Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)
ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 24
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures.
Time frame: Week 12
Percentage of Patients Achieving Minimal Disease Activity (MDA)
It uses a composite of 7 key outcome measures (includes PASI) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients' disease. The LEI is used to assess tender entheseal points. Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 1. TJC ≤1, 2. SJC ≤1, 3. PASI total score ≤1 or BSA ≤3, 4. patient pain VAS score of ≤15, 5. patient global VAS score of ≤20, 6. HAQ-DI score ≤0.5, 7. tender entheseal points (6 entheseal points) ≤1.
Time frame: Week 24
Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)
The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). So, "0" indicates good score here.
Time frame: Week 24
Change From Baseline in Itch Numeric Rating Scale (NRS)
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participants itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 12
Change From Baseline in Tender Joint Count (TJC)
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Swollen Joint Count (SJC)
SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Patients Global Assessment of Disease Activity VAS
The patient's overall assessment of his or her PsA activity will be recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Physicians Global Assessment of Disease Activity VAS
The investigator will be asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in C-Reactive Protein (CRP)
C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)
The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score
The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
Time frame: Baseline, Week 24
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)
Number of participants with positive treatment emergent anti-ixekizumab antibodies was summarized by treatment group.
Time frame: Week 24
Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab
The Ctrough is the minimum observed serum concentration at steady state of Ixekizumab. The Ctrough at Week 24 was reported.
Time frame: All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)
Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab
The AUC(Tau,Steady State) is the area under the concentration-time curve for dosing interval (Tau) at steady state of ixekizumab (Tau is 28 days for 80 mg Q4W cohort, and is 14 days for 80mg Q2W cohort, respectively).
Time frame: All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)
Percentage of Participants Achieving ACR 20
ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 52 and Week 156
Percentage of Participants Achieving ACR 50
ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 52 and Week 156
Percentage of Participants Achieving ACR 70
ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
Time frame: Week 52 and Week 156
| Milestone | Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period | Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period | Placebo (PBO) - Blinded Treatment Period | Ixe 80 mg Q2W - Blinded Treatment Period IR | Ixe 80 mg Q4W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period | Ixe 80 mg Q2W - Post Treatment Follow-Up Period | Ixe 80 mg Q4W - Post Treatment Follow-Up Period | PBO - Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 123 | 122 | 118 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received atleast one dose of study drug | 123 | 122 | 118 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 109 | 111 | 94 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 14 | 11 | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 5 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 2 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Failure to meet randomization | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period | Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period | Placebo (PBO) - Blinded Treatment Period | Ixe 80 mg Q2W - Blinded Treatment Period IR | Ixe 80 mg Q4W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period | Ixe 80 mg Q2W - Post Treatment Follow-Up Period | Ixe 80 mg Q4W - Post Treatment Follow-Up Period | PBO - Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 17 | 15 | 16 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 16 | 15 | 16 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period | Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period | Placebo (PBO) - Blinded Treatment Period | Ixe 80 mg Q2W - Blinded Treatment Period IR | Ixe 80 mg Q4W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period | Ixe 80 mg Q2W - Post Treatment Follow-Up Period | Ixe 80 mg Q4W - Post Treatment Follow-Up Period | PBO - Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 107 | 111 | 46 | 46 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55 | 70 | 20 | 23 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 52 | 41 | 26 | 23 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 25 | 19 | 18 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 9 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Unknown/missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period | Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period | Placebo (PBO) - Blinded Treatment Period | Ixe 80 mg Q2W - Blinded Treatment Period IR | Ixe 80 mg Q4W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period | Ixe 80 mg Q2W - Post Treatment Follow-Up Period | Ixe 80 mg Q4W - Post Treatment Follow-Up Period | PBO - Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 142 | 145 | 17 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 133 | 137 | 16 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 8 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Unknown/missing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 |
ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).
| Percentage of Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) | 19.5 | 53.3 | 48.0 |
HAQ-DI is a participant reported questionnaire that measures disease-associated disability(physical function).It consists of 24 questions with 8 domains: dressing/grooming,arising,eating,walking,hygiene,reach,grip and other daily activities. The disability section scores the participant's self-perception on degree of difficulty (0=without any difficulty,1=with some difficulty,2=with much difficulty,3=unable to do)covering the 8 domains.The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.The reported use of special aids/devices and/or the need for assistance of another person to perform these activities is assessed.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment,baseline score,geographic region, TNFi experience,visit, treatment-by-visit interaction(itcn), geographic region-by-visit itcn,TNFi experience-by-visit itcn and baseline score-by-visit itcn.
| units on a scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score | -0.2 ± 0.08 | -0.6 ± 0.07 | -0.4 ± 0.07 |
ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| Percentage of Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving ACR20 | 22.0 | 50.0 | 48.0 |
ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| Percentage of Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50) | 5.1 | 35.2 | 33.3 |
ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| Percentage of Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70) | 0 | 22.1 | 12.2 |
The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures.
| Percentage of Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75 | 10.4 | 57.4 | 61.8 |
It uses a composite of 7 key outcome measures (includes PASI) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients' disease. The LEI is used to assess tender entheseal points. Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 1. TJC ≤1, 2. SJC ≤1, 3. PASI total score ≤1 or BSA ≤3, 4. patient pain VAS score of ≤15, 5. patient global VAS score of ≤20, 6. HAQ-DI score ≤0.5, 7. tender entheseal points (6 entheseal points) ≤1.
| Percentage of Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Patients Achieving Minimal Disease Activity (MDA) | 3.4 | 27.9 | 23.6 |
The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). So, "0" indicates good score here.
| Percentage of Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI) | 21.7 | 35.3 | 31.0 |
The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participants itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Itch Numeric Rating Scale (NRS) | -0.7 ± 0.40 | -3.4 ± 0.39 | -3.3 ± 0.39 |
TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Tender Joint Count | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Tender Joint Count (TJC) | -6.2 ± 1.96 | -12.7 ± 1.87 | -12.5 ± 1.77 |
SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Swollen Joint Count | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Swollen Joint Count (SJC) | -5.0 ± 1.05 | -8.5 ± 0.99 | -7.4 ± 0.94 |
The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS) | -21.4 ± 3.97 | -36.9 ± 3.74 | -33.5 ± 3.58 |
The patient's overall assessment of his or her PsA activity will be recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Patients Global Assessment of Disease Activity VAS | -19.0 ± 3.91 | -40.7 ± 3.68 | -37.3 ± 3.53 |
The investigator will be asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Physicians Global Assessment of Disease Activity VAS | -18.3 ± 3.98 | -40.0 ± 3.85 | -37.9 ± 3.75 |
C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| milligram per liter (mg/L) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in C-Reactive Protein (CRP) | -3.6 ± 1.87 | -11.8 ± 1.76 | -9.8 ± 1.68 |
The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Disease Activity Score-CRP (DAS28-CRP) | -0.8 ± 0.20 | -2.1 ± 0.19 | -1.8 ± 0.18 |
The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score | -2.1 ± 0.38 | -3.7 ± 0.36 | -3.6 ± 0.35 |
The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score | -0.7 ± 0.37 | -2.0 ± 0.35 | -2.1 ± 0.34 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS) | 3.3 ± 1.36 | 8.9 ± 1.29 | 8.2 ± 1.23 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.
| Units on a Scale | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS) | 0.9 ± 1.32 | 3.6 ± 1.24 | 4.0 ± 1.18 |
Number of participants with positive treatment emergent anti-ixekizumab antibodies was summarized by treatment group.
| Participants | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|---|
| Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA) | 1 | 8 | 4 |
The Ctrough is the minimum observed serum concentration at steady state of Ixekizumab. The Ctrough at Week 24 was reported.
| micograms per milliliter (mcg/mL) | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|
| Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab | 2.46 ± 79.1 | 7.96 ± 71.1 |
The AUC(Tau,Steady State) is the area under the concentration-time curve for dosing interval (Tau) at steady state of ixekizumab (Tau is 28 days for 80 mg Q4W cohort, and is 14 days for 80mg Q2W cohort, respectively).
| mcg*day/mL | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab | 141 ± 59.3 | 143 ± 57.5 |
ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| Percentage of participants | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period |
|---|---|---|---|---|
| Week 52 | 58.9 | 67.6 | 50.0 | 60.9 |
| Week 156 | 42.1 | 50.5 | 39.1 | 45.7 |
ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| Percentage of participants | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period |
|---|---|---|---|---|
| Week 52 | 38.3 | 45.9 | 34.8 | 43.5 |
| Week 156 | 29.0 | 35.1 | 26.1 | 34.8 |
ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.
| Percentage of participants | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period |
|---|---|---|---|---|
| Week 52 | 20.6 | 28.8 | 15.2 | 23.9 |
| Week 156 | 22.4 | 21.6 | 10.9 | 19.6 |
Collected over Baseline Up To 2.55 Years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period | — | 8/123 (6.5%) | 58/123 (47.2%) |
| Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period | — | 3/122 (2.5%) | 58/122 (47.5%) |
| Placebo (PBO) - Blinded Treatment Period | — | 4/118 (3.4%) | 40/118 (33.9%) |
| Ixe 80 mg Q2W - Blinded Treatment Period IR | — | 0/17 (0%) | 5/17 (29.4%) |
| Ixe 80 mg Q4W - Blinded Treatment Period IR | — | 0/15 (0%) | 8/15 (53.3%) |
| PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR | — | 0/16 (0%) | 11/16 (68.8%) |
| PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR | — | 1/16 (6.3%) | 8/16 (50%) |
| Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | — | 10/107 (9.3%) | 59/107 (55.1%) |
| Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | — | 13/111 (11.7%) | 65/111 (58.6%) |
| Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | — | 6/46 (13%) | 20/46 (43.5%) |
| Placebo/ Ixe 80 mg Q4W - Extended Treatment Period | — | 3/46 (6.5%) | 32/46 (69.6%) |
| Ixe 80 mg Q2W - Post Treatment Follow-Up Period | — | 1/142 (0.7%) | 16/142 (11.3%) |
| Ixe 80 mg Q4W - Post Treatment Follow-Up Period | — | 2/145 (1.4%) | 13/145 (9%) |
| PBO - Post Treatment Follow-Up Period | — | 2/17 (11.8%) | 2/17 (11.8%) |
| Event | Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period | Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period | Placebo (PBO) - Blinded Treatment Period | Ixe 80 mg Q2W - Blinded Treatment Period IR | Ixe 80 mg Q4W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period | Ixe 80 mg Q2W - Post Treatment Follow-Up Period | Ixe 80 mg Q4W - Post Treatment Follow-Up Period | PBO - Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Knee arthroplastySurgical and medical procedures | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 1/16 | 0/107 | 0/111 | 0/46 | 0/46 | 0/142 | 0/145 | 0/17 |
| Postoperative wound infectionInfections and infestations | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 0/46 | 0/46 | 0/142 | 0/145 | 1/17 |
| Postoperative wound complicationInjury, poisoning and procedural complications | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 0/46 | 0/46 | 0/142 | 0/145 | 1/17 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 0/46 | 0/46 | 0/142 | 0/145 | 1/17 |
| Cardio-respiratory arrestCardiac disorders | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 1/46 | 0/46 | 0/142 | 0/145 | 0/17 |
| Basedow's diseaseEndocrine disorders | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 1/46 | 0/46 | 0/142 | 0/145 | 0/17 |
| Abdominal painGastrointestinal disorders | 0/123 | 0/122 | 1/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 0/46 | 1/46 | 0/142 | 0/145 | 0/17 |
| Colitis ulcerativeGastrointestinal disorders | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 0/46 | 1/46 | 0/142 | 0/145 | 0/17 |
| Inguinal herniaGastrointestinal disorders | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 1/46 | 0/46 | 0/142 | 0/145 | 0/17 |
| NauseaGastrointestinal disorders | 0/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 0/107 | 0/111 | 0/46 | 1/46 | 0/142 | 0/145 | 0/17 |
| Event | Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period | Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period | Placebo (PBO) - Blinded Treatment Period | Ixe 80 mg Q2W - Blinded Treatment Period IR | Ixe 80 mg Q4W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR | PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR | Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period | Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period | Placebo/ Ixe 80 mg Q2W - Extended Treatment Period | Placebo/ Ixe 80 mg Q4W - Extended Treatment Period | Ixe 80 mg Q2W - Post Treatment Follow-Up Period | Ixe 80 mg Q4W - Post Treatment Follow-Up Period | PBO - Post Treatment Follow-Up Period |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 12/123 | 12/122 | 9/118 | 0/17 | 0/15 | 1/16 | 0/16 | 20/107 | 15/111 | 4/46 | 8/46 | 2/142 | 1/145 | 0/17 |
| NasopharyngitisInfections and infestations | 4/123 | 9/122 | 4/118 | 0/17 | 1/15 | 0/16 | 0/16 | 15/107 | 20/111 | 6/46 | 4/46 | 3/142 | 5/145 | 0/17 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 1/50 | 0/63 | 0/56 | 0/5 | 0/9 | 0/10 | 0/9 | 1/46 | 1/56 | 1/24 | 3/20 | 0/64 | 0/72 | 0/9 |
| SinusitisInfections and infestations | 5/123 | 7/122 | 2/118 | 0/17 | 0/15 | 0/16 | 1/16 | 10/107 | 11/111 | 4/46 | 6/46 | 3/142 | 0/145 | 0/17 |
| Injection site erythemaGeneral disorders | 4/123 | 3/122 | 0/118 | 1/17 | 0/15 | 2/16 | 0/16 | 1/107 | 0/111 | 0/46 | 0/46 | 0/142 | 0/145 | 0/17 |
| Injection site reactionGeneral disorders | 15/123 | 6/122 | 1/118 | 2/17 | 1/15 | 2/16 | 1/16 | 6/107 | 2/111 | 4/46 | 5/46 | 0/142 | 0/145 | 0/17 |
| Injection site painGeneral disorders | 2/123 | 1/122 | 2/118 | 2/17 | 0/15 | 1/16 | 0/16 | 3/107 | 0/111 | 1/46 | 1/46 | 0/142 | 0/145 | 0/17 |
| Urinary tract infectionInfections and infestations | 4/123 | 6/122 | 3/118 | 0/17 | 0/15 | 0/16 | 0/16 | 6/107 | 7/111 | 1/46 | 5/46 | 2/142 | 0/145 | 2/17 |
| BronchitisInfections and infestations | 3/123 | 1/122 | 4/118 | 0/17 | 0/15 | 0/16 | 1/16 | 11/107 | 11/111 | 1/46 | 2/46 | 1/142 | 0/145 | 0/17 |
| GastritisGastrointestinal disorders | 1/123 | 0/122 | 0/118 | 0/17 | 0/15 | 0/16 | 0/16 | 1/107 | 0/111 | 0/46 | 4/46 | 0/142 | 0/145 | 0/17 |
All randomized participants.
| Age, Continuous(years) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Mean | 51.5 ± 10.39 | 52.6 ± 13.57 | 51.7 ± 11.85 | 51.9 ± 12.00 |
| Sex: Female, Male(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Female | 62 | 59 | 73 | 194 |
| Male | 56 | 63 | 50 | 169 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 11 | 11 | 13 | 35 |
| Not Hispanic or Latino | 106 | 109 | 109 | 324 |
| Unknown or Not Reported | 1 | 2 | 1 | 4 |
| Race (NIH/OMB)(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 7 | 7 | 7 | 21 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 1 | 1 | 1 | 3 |
| White | 108 | 111 | 113 | 332 |
| More than one race | 2 | 2 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Placebo | Ixekizumab 80 mg Q4W | Ixekizumab 80 mg Q2W | Total |
|---|---|---|---|---|
| Czechia | 8 | 4 | 8 | 20 |
| United States | 60 | 65 | 63 | 188 |
| Taiwan | 6 | 6 | 7 | 19 |
| Poland | 5 | 4 | 5 | 14 |
| Italy | 0 | 0 | 1 | 1 |
| United Kingdom | 5 | 6 | 5 | 16 |
| Australia | 2 | 2 | 3 | 7 |
| France | 6 | 6 | 5 | 17 |
| Germany | 11 | 13 | 12 | 36 |
| Spain | 15 | 16 | 14 | 45 |
Showing the first 100 of 109 sites across 10 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2014 to primary completion in Sep 2016, 20 months.
Results were first posted in Dec 2017, 1 year 3 months after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 20 months is below that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab